Vera Therapeutics appointed Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, while William Turner will transition to Special Advisor for Regulatory Affairs effective the same date.
| IndividualWilliam TurnerNancy Bowman, M.D., Ph.D. | RoleChief Regulatory Officer → Special Advisor for Regulatory AffairsChief Regulatory Officer | Type of ChangeTransitionAppointment | Effective DateAugust 3, 2026August 3, 2026 | ReasonNot disclosedNot disclosed | Replacement InfoSucceeded by Nancy Bowman, M.D., Ph.D.N/A | Background DetailsNot disclosedNot disclosed | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.